Radiopharm Theranostics (NASDAQ:RADX) Stock Jumps 2.1% – Here’s Why

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Get Free Report)’s share price shot up 2.1% during trading on Wednesday. The company traded as high as $0.7417 and last traded at $0.6851. Approximately 18,729 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 48,471 shares. The stock had previously closed at $0.6710.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Radiopharm Theranostics has an average rating of “Hold” and an average target price of $11.00.

Read Our Latest Stock Report on RADX

Radiopharm Theranostics Stock Up 2.1%

The stock has a 50 day moving average of $1.21 and a two-hundred day moving average of $3.41.

Radiopharm Theranostics (NASDAQ:RADX – Get Free Report) last released its earnings results on Friday, July 31st. The company reported ($0.81) EPS for the quarter. The business had revenue of $0.49 million during the quarter. As a group, research analysts anticipate that Radiopharm Theranostics Limited – Sponsored ADR will post -3.23 EPS for the current year.

About Radiopharm Theranostics

(Get Free Report)

Radiopharm Theranostics is an Australian clinical-stage biotechnology company developing radiopharmaceuticals for cancer imaging and treatment. Its theranostic approach uses radioactive compounds designed to help identify cancer and, in some cases, deliver targeted radiation to tumors. The company’s research programs span several types of targeting agents, including peptides, small molecules, antibodies and nanobodies. Its pipeline includes candidates in development for imaging or treating cancers such as brain, breast and kidney cancer.

Further Reading

Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.